key: cord-0312650-pfiq2vwu
authors: Shapiro, J. R.; Li, H.; Morgan, R.; Chen, Y.; Kuo, H.; Ning, X.; Shea, P.; Wu, C.; Merport, K.; Saldanha, R.; Liu, S.; Abrams, E.; Kelly, D. C.; Sheridan-Malone, E.; Wang, L.; Zeger, S. L.; Klein, S.; Leng, S. X.
title: Sex-specific effects of aging on the humoral immune response to repeat vaccination with the high-dose seasonal influenza vaccine in older adults
date: 2021-07-23
journal: nan
DOI: 10.1101/2021.07.21.21260712
sha: 10e0ce7560262e67d59db51a734c5fea8bbb3c44
doc_id: 312650
cord_uid: pfiq2vwu

Older adults ([≥]65 years of age) bear a significant burden of severe disease and mortality associated with influenza, despite relatively high annual vaccination coverage and substantial pre-existing immunity to influenza. To test the hypothesis that host factors, including age and sex, play a role in determining the effect of repeat vaccination and levels of pre-existing humoral immunity to influenza, we evaluated pre- and post-vaccination strain-specific hemagglutination inhibition (HAI) titers in adults over 75 years of age who received a high-dose influenza vaccine in at least four out of six influenza seasons (NCT02200276). Neither age, sex, body mass index, frailty, nor repeat vaccination were significantly associated with post-vaccination HAI titer outcomes. Pre-vaccination titers, however, were significantly predictive of post-vaccination outcomes. Pre-vaccination titers to H1N1 remained constant with age, while those to H3N2 and influenza B decreased substantially with age in males but not in females. Our findings highlight the importance of pre-existing immunity in this highly vaccinated older adult population and suggest that older males are particularly vulnerable to reduced pre-existing humoral immunity to influenza from previous annual vaccination.

Seasonal influenza is an important public health burden in older adults (people ≥65 59 years of age), particularly the oldest and frail subset 1-3 . In the United States (U.S.), there are an 60 estimated 4 million incident cases per year in older adults, accounting for 90% of deaths 61 associated with influenza 4,5 . The U.S. Centers for Disease Control and Prevention (CDC) 62 recommends annual influenza vaccination for prevention of influenza infection and 63 complications in people 6 months and older 6 . The high-dose inactivated influenza vaccine (HD-64 IIV) is available to older adults and has demonstrated superior efficacy over standard-dose 65 vaccines in this vulnerable age group 6,7 . Seasonal influenza vaccine coverage is relatively high in 66 older adults, with >60% of older Americans vaccinated annually, compared to <40% of the 18-67 49 age group 8 . 68

Age-related immunosenescence, defined by a decline in cellular and humoral immune 69 function combined with a chronic low-grade inflammatory phenotype (CLIP) 9-11 , is believed to 70 be the primary reason for the reduced effectiveness of influenza vaccines observed in older 71 adults 12-14 . Repeated annual vaccination may also have a negative effect on vaccine-induced 72 humoral immune responses as well as vaccine effectiveness (VE). For example, a recent 73 observational test-negative study using ten years of vaccination history found that in older 74 adults, VE decreased with increasing numbers of previous vaccinations but that vaccination 75 continued to offer some level of protection 15 . Another study over eight seasons in the general 76 adult population found that VE to H3N2, but not influenza B, was reduced among individuals 77 with frequent vaccination history compared to those without prior vaccination 16 . The impact of 78 repeat vaccination on H3N2 was confirmed by a meta-analysis, which found heterogeneous 79 effects of repeat vaccination overall; however, when negative effects were observed, they were 80 most pronounced for H3N2 17 . In contrast, a recent systematic review and meta-analysis 81 concluded that the available evidence does not support a reduction in VE with consecutive 82 repeat vaccination, but that certainty in the evidence was low 18 suppress the response to novel influenza virus strains by reducing the amount of available 95 antigen or epitope masking 23,24 . A theoretical benefit of HD-IIV is that pre-existing antibodies 96 cannot sequester the increased amount of antigen delivered, and, thus, more antigen is 97 available to activate memory B cells and elicit a protective response 25-27 . To our knowledge, 98 however, the impact of pre-existing immunity in the context of the HD-IIV has not been 99 adequately characterized. 100 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint

In addition to age, other host factors including sex, frailty, and body mass index (BMI) 101 can impact vaccine responses in older adults. Females have been found to mount greater 102 antibody responses to HD-IIV than males 28 . The relationship between frailty and influenza 103 vaccine responses is debated in the literature, with one study reporting frailty having a negative 104 effect 29 , others reporting no effect 30-34 , and others still reporting a positive effect 35 . Finally, in 105 older adults, obesity is significantly associated with decreased hemagglutination inhibition (HAI) 106 titers and percentage of switched memory B cells 36 . We hypothesize that the variation across 107 studies in estimates of the effects of pre-existing immunity and repeat annual vaccination is 108 partly caused by failure to adequately account for heterogeneity and interactions among host 109 factors that likely differ across studies. To address this knowledge gap, we used a longitudinal 110 cohort of older adults over 75 years of age who had received high-dose, trivalent inactivated 111 influenza vaccine (HD-IIV3) in at least four out of six influenza seasons to estimate the impact of 112 repeat vaccination on the antibody response to HD-IIV3 and its dependence on the intersection 113 of age, sex, frailty, BMI, pre-existing immunity. 114 115

Over the six influenza seasons from 2014-2015 to 2019-2020, 90 individuals participated 118 in at least four study seasons and 433 doses of HD-IIV3 were. The strains included in each 119 vaccine and the study protocol are described in Figure 1 . Table 1 shows demographic and 120 clinical characteristics of the study participants. There was a slight predominance of females 121 (55.6%), and yearly study enrollment increased over time. Baseline characteristics, measured 122 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint during the first year of participation, were similar between males and females. The median age 123 at study enrollment was 80, and >50% of participants were classified as pre-frail as per the 124 Frailty Phenotype 37 . Trends in the change in frailty since baseline, calculated as the difference 125 between the first and last years of participation, differed by sex. A greater proportion of males 126 improved in frailty status, whereas more females either did not change or progressed in frailty 127 status. A greater proportion of males also experienced changes in BMI over the course of the 128 study, while BMI did not change for females. 129 Pre-and post-vaccination strain-specific HAI titer outcomes to the three HD-IIV3 vaccine 133 antigens are summarized and disaggregated by sex in Table 2 . As expected in this highly 134 vaccinated elderly population, titers and seroprotection rates (defined as an HAI titer ≥40 38-40 ) 135 were high. This was particularly true for influenza B, where 98% of the participants were 136 seroprotected prior to immunization. Post-vaccination, >94% of participants achieved 137 seroprotection for H1N1 and H3N2, while 100% of participants were seroprotected against 138 influenza B. Because of the lack of variability in post-vaccination seroprotection, this outcome 139 was omitted from further analysis. Fold-rise in titers and rates of seroconversion, as defined by 140 ≥4-fold titer increase 41 , were relatively low but were highest for H3N2. There were no sex 141 differences in any post-vaccination outcomes. Together, these data indicate that pre-existing 142 and post-vaccination strain-specific HAI titers remained high among older adults who were 143 repeatedly vaccinated with HD-IIV3. 144 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We then assessed the relationships between pre-defined host factors (i.e., age, sex, 148 BMI, and frailty status) and post-vaccination strain-specific HAI titer outcomes. When 149 controlling for pre-vaccination titers and study year, neither age, frailty, nor BMI were 150 individually statistically-significantly associated with post-vaccine titers (Figure 2A-C The relationship between the number of years of study participation and post-158 vaccination HAI titers outcomes was investigated to address the concern of potential negative 159 effects of repeated annual vaccination on the humoral immune response to future vaccines. 160

Vaccination status prior to study enrollment could not be verified, but leveraging the 161 longitudinal design of our study, we sought to quantify whether post-vaccination outcomes 162 declined with additional annual vaccination, and whether this effect differed by sex. There was 163 generally a negative trend between the number of years participated and post-vaccination 164 titers ( Figure 3A-D) , fold rise in titers ( Figure 3E-H) , and odds of seroconversion ( Figure 3I-L) ; 165 these decreases, however, were not statistically significant. 166 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint Two interesting trends emerged from this analysis. First, the effect sizes were smaller 167 (i.e., closer to the null) for influenza B than for either H1N1 or H3N2, suggesting that the impact 168 of repeat vaccination may vary by influenza subtype. Secondly, there was a significant sex 169 difference in the effect of increasing years of vaccination on the odds of seroconverting to 170 H3N2 (difference in log odds = 0.38; p = 0.023). While there was no effect in females (OR = 171 0.988; p = 0.959), the odds of seroconverting to H3N2 decreased by 33% for each additional 172

year of study participation for males (OR = 0.673; p = 0.100) (Figure 3K-L) . Therefore, in 173 addition to varying by virus subtype, the mechanisms through which repeated vaccination 174 affects antibody responses may be sex-specific. Figure 4F ) 185 (p<0.0001 for testing the null hypotheses that the slope to zero for all antigens), such that 186 greater pre-vaccination titers were associated with a smaller fold rise. Finally, there was a 187 similar negative association between pre-vaccination titers and the odds of seroconverting for 188 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. there were no statistically significant sex differences in the effects of frailty or BMI on pre-205 vaccination HAI titers against either H1N1, H3N2, or influenza B. A statistically significant sex by 206 age interaction, however, was observed for H3N2 ( Figure 5B ) and for influenza B (Figure 5C ), in 207 which HAI titers declined with age among male but not female participants. 208

To further interrogate the sex-specific effects of aging, expanded models controlling for 209 frailty and BMI, in addition to study year, were constructed. Coefficients from the base (i.e., 210 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint controlling for study year only) and expanded models are shown in Table 3 , and results from 211 expanded models are plotted in Figure 5D -F. For H1N1, HAI titers tended to increase with age 212 for both males and females, but the increase was not statistically significant (males: 0. Figure 5F ). Like H3N2, the sex difference in the effect of age was significant 220 for influenza B (p = 0.005). 221

Both the base and expanded models were then amended to include cubic splines to 222 obtain more granular estimates of the effects of age on HAI titers for males and females. 223

Coefficients for both base and expanded non-linear models are shown in Table 3 , and results 224 from expanded models are plotted in Figure 5G -I. The non-linear model for H1N1 did not differ 225 from the linear model, and no significant effects of age within each sex or difference between 226 the sexes were observed ( Figure 5G ). Although the trends in the linear models were similar for 227 H3N2 and influenza B, using age as a non-linear predictor revealed that different age categories 228 were driving the overall effects. For H3N2, the increase in pre-vaccination HAI titers with age in 229 females was driven by individuals in the 80-85 age category (increase of 0.67 units; p = 0.037), 230 and the decrease in males was driven primarily by people in the 75-80 age category (decrease 231 of 1.78 units; p = 0.012) (Figure 5.H) . Thus, the sex difference was greatest at the younger end 232 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint of the cohort (p = 0.036 at 75 years of age). Conversely, increasing titers to influenza B with age 233 in females were driven by individuals in the 75-80 age category (increase of 1.2 units; p = 234 0.004), whereas for males there was a sharp decline in HAI titers that occurred in participants 235 90-95 years of age (decrease of 1.65 units; p < 0.0001) (Figure 5.I) . Here, the sex difference in 236 pre-vaccination titers was only significant at the oldest end of the cohort (p = 0.003 at 95 years 237 of age). Taken together, these data illustrate sex-specific effects of aging on pre-vaccination 238 antibody titers to H3N2 and influenza B, but not H1N1. 239 240

The impact of sex as a biological variable is often ignored in biomedical research 42, 43 . 242 This is particularly true in the context of aging, where attention is typically directed to 243 immunosenescence, failing to recognize that aging can have distinct effects on immune 244 function in males and females [44] [45] [46] . In this analysis, a priori hypotheses regarding sex differences 245 in the effect of age guided the inclusion of age by sex interaction terms in all models. To 246 illustrate the consequences of ignoring sex as a biological variable, however, analyses were 247 repeated controlling for sex rather than allowing age effects to vary by sex. For H3N2 and 248 influenza B, where the effect of aging was found to be statistically significantly different in 249 males as compared to females, the estimates derived by controlling for sex (black lines in Figure  250 5E, F, H, I) were not representative of either sex. In the linear models, for example, controlling 251 for sex led to the incorrect inference that titers remain constant with age, while the interaction 252 models demonstrate that this is false for both males and females. 253 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In addition to conceptual reasons to interrogate sex differences, inclusion of interaction 254 terms improved the goodness-of-fit of statistical models. Goodness-of-fit of eight models for 255 each vaccine antigen were compared using Akaike's Information Criterion (AIC) in Table 4,  256 where lower values indicate better relative goodness-of-fit. For antibody titers to H3N2 and 257 influenza B, despite the penalty for increasing model complexity, fit was improved by including 258 an age-sex interaction term, and the best models overall were expanded models that allowed 259 the effect of age to differ by sex. Thus, incorporating sex differences into vaccinology research 260 can lead to more robust analysis. 261

Discussion 263

In this multi-season, longitudinal study of older adults over 75 years of age, we observed 264 no statistically significant associations of age, sex, BMI, frailty, or the number of years of repeat 265 annual vaccination with any post-vaccination HAI titer outcomes. Importantly, this suggests 266 that repeat annual vaccination with HD-IIV3 does not seem to have significant positive or 267 negative effects on strain-specific HAI antibody responses in the highly vaccinated elderly 268 population but may mask the impact of other factors. Interestingly, there was some evidence to 269 suggest that particularly for H3N2, the effect of repeat vaccination does vary by sex, thus 270 supporting our hypothesis that variability in estimates of the effect of repeat vaccination in the 271 literature is caused by failure to adequately account for the contribution of host factors. 272

Pre-vaccination titers strongly predicted all post-vaccination antibody titer outcomes, 273

indicating that pre-existing humoral immunity, which may reflect the durability of humoral 274 immunity against influenza from previous seasons, is an important outcome measure to 275 consider in the highly vaccinated older adult population. Regarding age as a determinant of pre-276 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint existing humoral immunity, we found that HAI titers to all three vaccine antigens stayed 277 constant in females with age but that HAI titers to H3N2 and influenza B decreased with age in 278 males, leading to significant sex differences in the effect of age for these two viruses. It has 279 previously been reported that at older ages, there is a male-bias in influenza B infection and 280 hospitalization 47,48 . Our results thus provide a potential mechanism for this sex difference and 281 highlight the need to develop better vaccines or vaccination strategies for older males. argue that high levels of pre-existing antibodies interfere with the generation of de novo 298 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint immune responses 24,27 , others suggest that ratio-based measures simply do not appropriately 299 control for imbalances in levels of pre-existing humoral immunity 50 . Following the latter 300 interpretation, a "ceiling effect" is evident in our data, whereby the limit of detection of the 301 assay prohibits observing seroconversion or a large fold-rise in individuals with high levels of 302 pre-existing humoral immunity. Particularly important in older adults, where formation of de 303 novo responses is impaired by immunosenescence 51 , the breadth of pre-existing humoral 304 immunity and the positive predictive value for post-vaccination titers can thus be harnessed to 305 elicit protection 26 . The clinical and scientific implications of this notion are far-reaching and 306 long-term, as the Advisory Committee on Immunization Practices (ACIP) of the CDC has 307 recommended annual influenza vaccination for anyone aged 6 months and older since 2010 52 . 308

For many vaccines, antibody titers wane over time [53] [54] [55] [56] . Influenza vaccines are unique in 309 this respect due to the recommendation for yearly immunization and exceptional antigenic 310 diversity, which alter the dynamics of waning immunity. The constant pre-vaccination HAI titers 311 with age in females seen in our study suggest that females benefit from a booster effect from 312 each successive annual vaccination that appears to prevent antibody waning. This influenza-313 specific effect has been reported elsewhere, where samples collected from individuals over a 314 20-year period revealed longitudinal increases in neutralizing titers to influenza 57 . As an 315 explanation for their findings, the authors suggest that even as viral antigens drift over time, 316 many epitopes remain conserved. These conserved epitopes stimulate memory B cells that 317 were generated in response to previous exposures, thus periodically boosting steady-state 318 immunity 57 . However, our data suggest that this effect is absent in males for H3N2 and 319 influenza B. The reasons for this sex difference are unknown, but may be attributable to the 320 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint compounding effects of females developing stronger responses to influenza infection and 321 vaccination throughout adulthood 58 , leading to a more robust repertoire of memory B cells that 322 recognize conserved epitopes on drifted virus strains. It is speculated that in older adults, 323 consistently inferior responses among males may manifest as a lack of memory B cells that can 324 be boosted by drifted viruses to counteract waning of antibody over time, thus resulting in 325 decreasing pre-vaccination titers with age. 326

Notably the sex difference was absent for H1N1. A possible explanation for this lies in 327 the differing evolutionary rates of the three viral strains. H1N1 experiences slower evolution 328 than H3N2 59 and the influenza B/Victoria lineage 60 . In addition, the global co-circulation of 329 B/Yamagata and B/Victoria lineages leads to increased exposure to divergent antigens 61 . 330 Accordingly, over the six influenza seasons included in our study, vaccine antigens were 331 significantly more variable for H3N2 and influenza B than for H1N1. While three H1N1 strains 332 were included in seasonal vaccines, five H3N2 strains and four influenza B strains were included 333 over the six study years. A decade-long review of the number of divergent vaccine strains that 334 our study participants may have been exposed to indicates that since 2010, the number of 335 H1N1 vaccine strains remained at a total of three, while seven H3N2 strains and five influenza B 336 were used in trivalent vaccines over this period 62 . It is thus possible that repeated exposure to 337 the same H1N1 antigen sufficiently boosted male steady-state immunity to mask sex 338 differences in the immune response. Conversely, for H3N2 and influenza B, sequential exposure 339 to drifted virus strains required robust and broad responses to allow for boosting of steady-340 state immunity, which may have only been present in females. 341 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint Another possible explanation is immunological imprinting in youth, as it has a lifelong 342 impact on subsequent immune responses to influenza infection and vaccination 22,63 . Individuals 343 in our cohort, born from 1916-1941, may have been exposed to H1N1 in their youth, while the 344 1918 pandemic virus continued to circulate, but were likely exposed to H3N2 and influenza B 345 later in life 64 . Accordingly, older adults are more likely to have HAI activity against historical 346 strains of H1N1 viruses than younger subjects, but also have more restricted reactivity to 347 historical H3N2 viruses 65 . Older cohorts are also relatively protected against symptomatic H1N1 348 infection compared to younger cohorts, but this pattern is reversed for H3N2 66,67 . It is therefore 349 possible that strong immune imprinting to H1N1 virus strains masked the sex differences 350 otherwise observed for H3N2 and influenza B. 351

Our study had several strengths and limitations. First, this was an observational study 352 that was not specifically designed to interrogate sex differences in the immune response to 353 influenza vaccination. To overcome small yearly sample sizes, six influenza seasons were pooled 354 together, and statistical methods were used to control for annual variation in vaccine viruses 355 and repeated measurements on participants. The resulting multi-season nature of this work 356 improves generalizability to future influenza seasons. Secondly, the humoral immune response 357 to vaccination was solely based on strain-specific HAI titers, which are the standard in the field, 358 but lack the functional quality of microneutralization assays 68 . Relying solely on serological 359 samples also prohibited more in-depth mechanistic investigation at the cellular level. Third, the 360 lack of racial diversity in our cohort must be noted, as it prohibited us from investigating race as 361 a host factor of interest, which should be considered in future studies. Although the study 362 lacked racial diversity, the cohort was diverse in terms of age at vaccination, allowing us to 363 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint study effects in the 'oldest' old subset. Finally, a major strength of this study is the 364 intersectional approach to this analysis, which allowed for interrogation of effects both 365 between and within groups (i.e., between and among males and females), leading to a richer 366 and more nuanced interpretation 69 . 367

In conclusion, we demonstrated that in highly vaccinated older adults, pre-vaccination 368 HAI titers, rather than age, sex, BMI, frailty, or repeat vaccination, predict post-vaccination 369 parameters of humoral immunity. Further, these pre-vaccination titers change with age in a 370 sex-specific manner such that older males are particularly vulnerable to lower levels of pre-371 existing humoral immunity. Further research should focus on elucidating the mechanisms 372 underlying this sex difference, as well as novel vaccination strategies to harness the breadth of 373 pre-existing immunity in older adults and better protect this vulnerable population. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint After a pre-vaccination blood draw, participants received HD-IIV3 (Fluzone®High-Dose Sanofi 386

Pasteur, PA, USA). A second blood sample was collected 21 to 28 days after vaccine 387 administration (Figure 1) 

A validated HAI assay was used to quantify antibody titers against study vaccine 397 antigens for the three vaccine strains (H1N1, H3N2 and B) in each year and were performed by 398 Sanofi Pasteur as previously described 70 . Briefly, serum was incubated with type III 399 neuraminidase to eliminate non-specific inhibitors and then with turkey red blood cells to 400 adsorb non-specific agglutinins. Sera were then serially diluted in duplicate, beginning at a 1:10 401 dilution, and incubated with influenza virus (4 hemagglutination units/25µl). Turkey red blood 402 cells were then added, and the titer defined as the highest dilution in which hemagglutination 403 was inhibited. 404 405

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint Sex was used as a dichotomous variable based on self-report. Age was calculated based 407 on the date of vaccination and used as a continuous variable. The frailty assessment was based 408 on the presence or absence of five measurable characteristics: slowed motor performance (by 409 walking speed), poor endurance and energy (by self-report of exhaustion), weakness (by grip 410 strength), shrinking (by unintentional weight loss), and low physical activity (self-report) 29,37 . 411

Participants with three or more out of these five characteristics were defined as frail, those 412 with one or two as prefrail, and those with none as non-frail. BMI was calculated based on 413 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint

To account for repeated measures on participants, multi-level mixed effects models 430 with random intercepts on the individual were used. Following standard risk factor analysis 431 procedure, the contributions of host factors of interest were first assessed individually. Based 432 on the a priori hypotheses of this analysis, fixed effects of the base models for post-vaccination 433 outcomes adjusted for study year, pre-vaccination titers and included interaction terms to 434 allow the effect of the host factor to differ for males and females. Fixed effects of the base 435 models for pre-vaccination titers adjusted for study year and included interaction terms to 436 allow effects to differ by sex. Where significant sex differences were found, further analysis 437 controlled for additional covariates, and used cubic B-splines to investigate non-linear 438 relationships 71 . The relative goodness-of-fit of various models were compared using Akaike's 439 Information Criterion. For graphs, predictions were capped at 95 years of age due to low 440 sample size and large uncertainty in estimates above 95 years. Coefficients were considered 441 statistically significant if 95% confidence intervals did not span the null value of zero (i.e., 442 p<0.05). Analysis was performed in Stata 15 (StataCorp). 443 444

The data that support the findings of this study are available from the corresponding 446 author upon request. 447 448 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preventing influenza in healthy adults. Cochrane database of systematic reviews (2018). 507 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint

The relationship between increasing years of vaccination and log2-transformed post-vaccination 698 HAI titers are shown for each vaccine antigen (a-c), with slopes summarized (d). Similarly, the 699 relationship between increasing years of vaccination and the log10-transformed fold-rise in 700 titers are shown for H1N1, H3N2, and influenza B (e-g), with the slopes summarized (h). The 701 relationship between increasing years of vaccination and probability of seroconversion are 702 shown for antibody responses against H1N1, H3N2, and influenza B, respectively (i-k), with the 703 logs odds ratios summarized (I). All models controlled for study year, pre-vaccination titers, and 704 age at vaccination. Whole-population models controlled for sex, while sex-specific estimates 705 were derived from models including an interaction term between sex and years of participation 706 and are shown with 95% confidence intervals. Asterisks indicate significant sex differences. 707 708 Relationships between log2-transformed pre-vaccination HAI titers and log2-transformed post-711 vaccination titers are shown for responses to H1N1, H3N2, and influenza B, respectively (a-c), 712 with slopes summarized (d). The relationships between pre-vaccination HAI titers and the log10-713 transformed fold-rise in titers are shown for each vaccine antigen (e-g), with the slopes 714 summarized (h). The relationships between pre-vaccination HAI titers and the probability of 715 seroconversion are shown for H1N1, H3N2, and influenza B, respectively (i-k), with the log odds 716 ratios summarized (l). All models controlled for study year. Overall estimates controlled for sex, 717 while sex-specific estimates were derived from models that included an interaction term 718 between sex and pre-vaccination titers and are shown with 95% confidence intervals. 719 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint Estimates for the relationship of age in decades (Age/10), frailty status, and BMI (five-unit 723 intervals, BMI/5) to pre-vaccination HAI titers were derived from multilevel mixed-effects 724 models controlling for study year for H1N1 (a), H3N2 (b), and influenza B (c). Expanded age 725 models controlling for frailty and BMI are shown for responses to H1N1 (d), H3N2 (e), and 726

influenza B (f). Expanded models for responses to H1N1 (g), H3N2 (h), and influenza B (I) were 727 then amended to include cubic B-splines for age with knots at 5-year intervals. Models for the 728 whole study population adjusted for sex, while sex-specific estimates included an interaction 729 term allowing effects to differ by sex and are shown with 95% confidence intervals. Asterisks 730 indicate significant sex differences. 731 732 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 23, 2021. ; https://doi.org/10.1101/2021.07.21.21260712 doi: medRxiv preprint Tables 733 Table 1 . Summary of study population characteristics 734 Table 2 . Pre-and post-vaccination hemagglutination antibody inhibition (HAI) titer outcomes 736 

Influenza vaccine effectiveness to prevent influenza-related 508 hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 509 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research 510 Network (CIRN) Serious Outcomes Surveillance (SOS Network)

Effectiveness of influenza vaccines in preventing severe influenza illness 513 among adults: a systematic review and meta-analysis of test-negative design case-514 control studies

The impact of repeated vaccination using 10-year vaccination history 516 on protection against influenza in older adults: a test-negative design study across the 517 2010/11 to 2015/16 influenza seasons in Ontario

Impact of Repeated Vaccination on Vaccine Effectiveness Against 520 Influenza A(H3N2) and B During 8 Seasons

Repeated annual influenza vaccination and vaccine effectiveness: 523 review of evidence

Does consecutive influenza vaccination reduce protection against 526 influenza: A systematic review and meta-analysis

Repeated Vaccination Does Not Appear to Impact Upon Influenza 529 Vaccine Effectiveness Against Hospitalization With Confirmed Influenza

Repeated influenza vaccination for preventing severe and fatal influenza 532 infection in older adults: a multicentre case-control study

Impact of repeated influenza 535 vaccinations in persons over 65 years of age: A large population-based cohort study of 536 severe influenza over six consecutive seasons

Preexisting influenza specific immunity and vaccine effectiveness

From Original Antigenic Sin to the 542 Universal Influenza Virus Vaccine

Influenza Immunization in the Context of Preexisting Immunity

Cell Responses against Influenza Viruses: 547 Short-Lived Humoral Immunity against a Life-Long Threat

Harnessing immune history to combat influenza viruses

Immunological assessment of influenza vaccines and immune 594 correlates of protection

Stop 'controlling' for sex and gender in global 597 health research

The Xs and Y of immune responses to viral vaccines

Commentary for the 'VSI: Aging and sex in immunity

Age-associated changes in the impact of sex steroids on influenza 604 vaccine responses in males and females

The Confluence of Sex Hormones and 607 Aging on

Influenza infections in Australia 2009-2015: is 610 there a combined effect of age and sex on susceptibility to virus subtypes? BMC 611 Infectious Diseases 19

Age and Sex Differences in Rates of Influenza-Associated 613 Hospitalizations in Hong Kong

Sex-specific effects of age and body mass index on antibody responses to 616 seasonal influenza vaccines in healthcare workers

Statistics in Clinical Vaccine Trials -Adjusting for Imbalance in Pre-Vaccination 618

Biology of Immune Responses to Vaccines in Elderly Persons

Estimating age-626 specific vaccine effectiveness using data from a large measles

/15: evidence for waning immunity

Durability of humoral immune responses to rubella following MMR 629 vaccination

A multisite study of pertussis vaccine effectiveness by time since last 631 vaccine dose from three Canadian provinces: A Canadian Immunization Research 632 Network study

The success of a universal hepatitis B immunization program as part 634 of Thailand's EPI after 22 years' implementation

Neutralizing Antibodies Against Previously Encountered Influenza 636 Virus Strains Increase over Time: A Longitudinal Analysis

Sex and Gender Differences in the 638 Outcomes of Vaccination over the Life Course

Antigenic patterns and evolution of the human influenza A (H1N1) virus. 641

The contrasting phylodynamics of human influenza B viruses

The epidemiological signature of influenza B virus and its B/Victoria and 645 B/Yamagata lineages in the 21st century

World Health Organization. WHO recommendations on the composition of influenza 648 virus vaccines

Recalling the Future: Immunological Memory Toward Unpredictable 651 Influenza Viruses

The evolving history of influenza viruses and influenza vaccines

Impact of age and pre-existing influenza immune responses in humans 656 receiving split inactivated influenza vaccine on the induction of the breadth of 657 antibodies to influenza A strains

Differences in patient age 660 distribution between influenza A subtypes

Childhood immune imprinting to influenza A shapes birth year-662 specific risk during seasonal H1N1 and H3N2 epidemics

Correlates of Protection against Influenza in the Elderly: Results 665 from an Influenza Vaccine Efficacy Trial

COVID-19: use intersectional analyses to close 668 gaps in outcomes and vaccination

Safety and immunogenicity of a quadrivalent inactivated 670 influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults

Sensible parameters for univariate and multivariate splines

All rights reserved. No reuse allowed without permission

which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Pre-vaccination -GMT (95% CI)

Pre-vaccination -GMT (95% CI)

B Pre-vaccination -GMT (95% CI)

* Sex difference p-values derived from multi-level linear (GMT) or logistic regressions (SPR and SCR)

Abbreviations & definitions: CI: confidence interval; Fold-rise: post-vaccination titer divided by pre-vaccination titer, transformed on the log10 739 scale; GMT: geometric mean titer; SPR: seroprotection rate, the proportion of individuals who achieved a titer ≥40